Details for New Drug Application (NDA): 021711
✉ Email this page to a colleague
The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.
Summary for 021711
| Tradename: | ABLAVAR |
| Applicant: | Lantheus Medcl |
| Ingredient: | gadofosveset trisodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 2440MG/10ML (244MG/ML) | ||||
| Approval Date: | Dec 22, 2008 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 3660MG/15ML (244MG/ML) | ||||
| Approval Date: | Dec 22, 2008 | TE: | RLD: | No | |||||
Expired US Patents for NDA 021711
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | ⤷ Get Started Free | ⤷ Get Started Free |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | ⤷ Get Started Free | ⤷ Get Started Free |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
